ישראל - עברית - Ministry of Health

trima israel pharmaceutical products maabarot ltd - valerian dry extract - טבליות מצופות פילם - valerian dry extract 500 mg - other hypnotics and sedatives - sedative in states of tension, nervousness and insomnia.

ישראל - עברית - Ministry of Health

a. levy dental co. ltd, israel - articaine hydrochloride; epinephrine as bitartrate - תמיסה להזרקה - articaine hydrochloride 40 mg/ml ml; epinephrine as bitartrate 5 mcg/ml ml - articaine, combinations - articaine, combinations - for infiltration anaesthesia and nerve block anaesthesia in clinical dentistry. this includes local or loco-regional dental anaesthesia.

ישראל - עברית - Ministry of Health

a. levy dental co. ltd, israel - articaine hydrochloride; epinephrine as bitartrate - תמיסה להזרקה - articaine hydrochloride 40 mg/ml ml; epinephrine as bitartrate 10 mcg/ml ml - articaine, combinations - articaine, combinations - for infiltration anaesthesia and nerve block anaesthesia in clinical dentistry. this includes local or loco-regional dental anaesthesia.

ישראל - עברית - Ministry of Health

3m israel - articaine hydrochloride; epinephrine hydrochloride - תמיסה להזרקה - epinephrine hydrochloride 0.006 mg/ml; articaine hydrochloride 40 mg/ml - articaine - articaine - infiltration anesthesia and nerve-block in dentistry. ubistesin is especially indicated for routine interventions such as: uncomplicated single and serial extractions. cavity and coronal stump preparations.

ישראל - עברית - Ministry of Health

3m israel - articaine hydrochloride; epinephrine hydrochloride - תמיסה להזרקה - epinephrine hydrochloride 0.012 mg/ml; articaine hydrochloride 40 mg/ml - articaine - articaine - infiltration anesthesia and nerve-block in dentistry. ubistesin is especially indicated for interventions requiring deep anesthesia and pronounced restriction of blood flow such as: - gingival and bone surgery - pulp surgery (amputation and extirpation) - extraction and trepanation of desmotic teeth and extraction of fractured teeth (osteotomy) - protracted surgical procedures i.e. caldwell-luc operation percutaneous osteosynthesis cystectomy mucogingival operations apicectomy.

ישראל - עברית - Ministry of Health

henry schein shvadent (2009 ) ltd - articaine hydrochloride; epinephrine bitartrate - תמיסה להזרקה - epinephrine bitartrate 0.031 mg / 1.7 ml; articaine hydrochloride 68 mg / 1.7 ml - articaine

ישראל - עברית - Ministry of Health

henry schein shvadent (2009 ) ltd - articaine hydrochloride; epinephrine bitartrate - תמיסה להזרקה - epinephrine bitartrate 0.015 mg / 1.7 ml; articaine hydrochloride 68 mg / 1.7 ml - articaine

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - אבקה להכנת תמיסה מרוכזת לעירוי - abatacept 250 mg - abatacept - abatacept - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (dmards) including methotrexate (mtx) or a tnf-alpha inhibitor.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.polyarticular juvenile idiopathic arthritis:orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason.

ישראל - עברית - Ministry of Health

cartiheal (2009) ltd. - רופא - agili-c implant is a bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of focal articular cartilage and/or osteochondral defects. it is indicated for cartilage and/or bone repair. the implant serves as a scaffold for cellular and matrix ingrowth. the agili-c implant is expected to biodegrade within 6 – 12 months.